The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Open accessAbstract
Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This ASBMR report provides guidance on BP therapy duration with a risk-benefit perspective. Two trials provided evidence for long-term BP use. In the Fracture Intervention Trial Long-term Extension (FLEX), postmenopausal women receiving alendronate for 10 years had fewer clinical vertebral fractures than those switched to placebo after 5 years. In the HORIZON extension, women who received 6 annual infusions of zoledronic acid had fewer morphometric vertebral fractures compared with those switched to placebo after 3 years. Low hip T-score, between –2 and –2.5 in FLEX and below –2.5 in HORIZON extension, predicted a beneficial response to continued therapy. Hence, the Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered. In women at high risk, for example, older women, those with a low hip T-score or high fracture risk score, those with previous major osteoporotic fracture, or who fracture on therapy, continuation of treatment for up to 10 years (oral) or 6 years (intravenous), with periodic evaluation, should be considered. The risk of atypical femoral fracture, but not osteonecrosis of the jaw, clearly increases with BP therapy duration, but such rare events are outweighed by vertebral fracture risk reduction in high-risk patients. For women not at high fracture risk after 3 to 5 years of BP treatment, a drug holiday of 2 to 3 years can be considered. The suggested approach for long-term BP use is based on limited evidence, only for vertebral fracture reduction, in mostly white postmenopausal women, and does not replace the need for clinical judgment. It may be applicable to men and patients with glucocorticoid-induced osteoporosis, with some adaptations. It is unlikely that future trials will provide data for formulating definitive recommendations. © 2015 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
Johnell, O., & Kanis, J. A. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0172-4 · Cited by 4,704
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationDenosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationHarris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475 · cited 16×
“Although some side effects of BPs, such as gastroesophageal irritation and nephrotoxicity (see below), were recognized early as potential adverse effects, subsequent reports indicate that BP use may be associated with clinically serious but rare safety concerns, including osteonecrosis of the jaw (ONJ) and atypical fe…”
InfluentialLiberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Self-citationShane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Self-citationZoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Risk of New Vertebral Fracture in the Year Following a Fracture
Lindsay, R. (2001) · JAMA · doi:10.1001/jama.285.3.320 · Cited by 1,897
Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0707onj · Cited by 1,650
Meunier, P. J., Roux, C., Seeman, E., Ortolani, S., Badurski, J. E., Spector, T. D., Cannata, J., Balogh, A., Lemmel, E.-M., Pors-Nielsen, S., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa022436 · Cited by 1,638
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Self-citationKhan, A. A., Morrison, A., Hanley, D. A., Felsenberg, D., McCauley, L. K., O'Ryan, F., Reid, I. R., Ruggiero, S. L., Taguchi, A., Tetradis, S., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2405 · Cited by 1,353
Self-citationRuggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.009 · Cited by 1,328
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Shane, E., Burr, D., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.253 · Cited by 1,116
Self-citationReginster, J. Y., Seeman, E., De Vernejoul, M. C., Adami, S., Compston, J., Phenekos, C., Devogelaer, J. P., Curiel, M. D., Sawicki, A., Goemaere, S., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1774 · Cited by 1,071
Self-citationMarkers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
Garnero, P., Hausherr, E., Chapuy, M.-C., Marcelli, C., Grandjean, H., Muller, C., Cormier, C., Bréart, G., Meunier, P. J., & Dr. Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111021 · Cited by 989
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Self-citationAlendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071408 · Cited by 914
Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., & Ebetino, F. H. (2006) · Bone · doi:10.1016/j.bone.2005.05.003 · Cited by 862
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
Grossman, J. M., Gordon, R., Ranganath, V. K., Deal, C., Caplan, L., Chen, W., Curtis, J. R., Furst, D. E., McMahon, M., Patkar, N. M., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20295 · Cited by 708
Siris, E. S., Harris, S. T., Rosen, C. J., Barr, C. E., Arvesen, J. N., Abbott, T. A., & Silverman, S. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.8.1013 · Cited by 704
Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1494 · Cited by 700
Bisphosphonate Use and Atypical Fractures of the Femoral Shaft
Schilcher, J., Michaëlsson, K., & Aspenberg, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010650 · Cited by 695
Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis
Adachi, J. D., Bensen, W. G., Brown, J., Hanley, D., Hodsman, A., Josse, R., Kendler, D. L., Lentle, B., Olszynski, W., Ste.-Marie, L.-G., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370603 · Cited by 685
Reid, D. M., Hughes, R. A., Laan, R. F. J. M., Sacco-Gibson, N. A., Wenderoth, D. H., Adami, S., Eusebio, R. A., & Devogelaer, J.-P. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.1006 · Cited by 592
Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60250-6 · Cited by 527
Wallach, S., Cohen, S., Reid, D. M., Hughes, R. A., Hosking, D. J., Laan, R. F., Doherty, S. M., Maricic, M., Rosen, C., Brown, J., et al. (2000) · Calcified Tissue International · doi:10.1007/s002230001146 · Cited by 513
Ruggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Australian Endodontic Journal · doi:10.1111/j.1747-4477.2009.00213.x · Cited by 505
Saag, K. G., Zanchetta, J. R., Devogelaer, J., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K., & Warner, M. R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24879 · Cited by 493
Self-citationKendler, D. L., Roux, C., Benhamou, C. L., Brown, J. P., Lillestol, M., Siddhanti, S., Man, H.-S., Martin, J. S., & Bone, H. G. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090716 · Cited by 453
Incidence of atypical nontraumatic diaphyseal fractures of the femur
Dell, R. M., Adams, A. L., Greene, D. F., Funahashi, T. T., Silverman, S. L., Eisemon, E. O., Zhou, H., Burchette, R. J., & Ott, S. M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1719 · Cited by 441
Greenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R., Zanchetta, J. R., Blosch, C. M., Mathisen, A. L., Morris, S. A., Marriott, T. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00005 · Cited by 427
Self-citationBauer, D. C., Black, D. M., Garnero, P., Hochberg, M., Ott, S., Orloff, J., Thompson, D. E., Ewing, S. K., Delmas, P. D., & for the Fracture Intervention Trial Study Group (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040512 · Cited by 405
Self-citationThe relationship between the chemistry and biological activity of the bisphosphonates
Ebetino, F. H., Hogan, A.-M. L., Sun, S., Tsoumpra, M. K., Duan, X., Triffitt, J. T., Kwaasi, A. A., Dunford, J. E., Barnett, B. L., Oppermann, U., et al. (2011) · Bone · doi:10.1016/j.bone.2011.03.774 · Cited by 391
Eisman, J. A., Bogoch, E. R., Dell, R., Harrington, J. T., McKinney, R. E., McLellan, A., Mitchell, P. J., Silverman, S., Singleton, R., Siris, E., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1698 · Cited by 383
Self-citationGeographic and ethnic disparities in osteoporotic fractures
Cauley, J. A., Chalhoub, D., Kassem, A. M., & Fuleihan, G. E.-H. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.51 · Cited by 376
Hellstein, J. W., Adler, R. A., Edwards, B., Jacobsen, P. L., Kalmar, J. R., Koka, S., Migliorati, C. A., & Ristic, H. (2011) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2011.0108 · Cited by 363
Self-citationFliefel, R., Tröltzsch, M., Kühnisch, J., Ehrenfeld, M., & Otto, S. (2015) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2015.01.026 · Cited by 363
Greenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R. S., Zanchetta, J., Blosch, C. M., Mathisen, A. L., Morris, S. A., & Marriott, T. B. (2007) · Annals of Internal Medicine · Cited by 360
Self-citationINTERMITTENT ETIDRONATE THERAPY TO PREVENT CORTICOSTEROID- INDUCED OSTEOPOROSIS
Dachi, J. O. D. A., Ensen, W. I. G. B., Acques, J., Rown, B., Anley, D. A. H., Osse, R. O. J., Endler, D. A. L. K., Entle, B. R. L., Lszynski, W. O. O., Ouis, L., et al. (1997) · Cited by 360
Fracture risk and zoledronic acid therapy in men with osteoporosis
Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204061 · Cited by 359
Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis
Mellström, D. D., Sörensen, O. H., Goemaere, S., Roux, C., Johnson, T. D., & Chines, A. A. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0286-7 · Cited by 350
Bisphosphonates for Osteoporosis — Where Do We Go from Here?
Whitaker, M., Guo, J., Kehoe, T., & Benson, G. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1202619 · Cited by 337
Joint IOF-ECTS GIO Guidelines Working Group, Lekamwasam, S., Adachi, J. D., Agnusdei, D., Bilezikian, J., Boonen, S., Borgström, F., Cooper, C., Diez Perez, A., Eastell, R., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1958-1 · Cited by 335
Self-citationEffect of Osteoporosis Treatment on Mortality: A Meta-Analysis
Bolland, M. J., Grey, A. B., Gamble, G. D., & Reid, I. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0852 · Cited by 329
Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu544 · Cited by 312
Compston, J., Bowring, C., Cooper, A., Cooper, C., Davies, C., Francis, R., Kanis, J. A., Marsh, D., McCloskey, E. V., Reid, D. M., et al. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.05.013 · Cited by 304
Self-citationRyg, J., Rejnmark, L., Overgaard, S., Brixen, K., & Vestergaard, P. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090207 · Cited by 293
Schwartz, A. V., Bauer, D. C., Cummings, S. R., Cauley, J. A., Ensrud, K. E., Palermo, L., Wallace, R. B., Hochberg, M. C., Feldstein, A. C., Lombardi, A., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.11 · Cited by 289
Self-citationContinuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?
Black, D. M., Bauer, D. C., Schwartz, A. V., Cummings, S. R., & Rosen, C. J. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1202623 · Cited by 279
Self-citationMurad, M. H., Drake, M. T., Mullan, R. J., Mauck, K. F., Stuart, L. M., Lane, M. A., Abu Elnour, N. O., Erwin, P. J., Hazem, A., Puhan, M. A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3060 · Cited by 277 · cited 1×
“For detailed reviews on alternative osteoporosis therapies, the reader is directed to published reviews.((100,101)) In women previously treated with oral BPs, switching to denosumab was associated with greater increases in BMD and reduction of turnover markers than continued intake of ALN,((102)) RIS,((103)) and IBN,(…”
Self-citationEnsrud, K. E., Barrett-Connor, E. L., Schwartz, A., Santora, A. C., Bauer, D. C., Suryawanshi, S., Feldstein, A., Haskell, W. L., Hochberg, M. C., Torner, J. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040326 · Cited by 275
Self-citationAndrews, E. B., Gilsenan, A. W., Midkiff, K., Sherrill, B., Wu, Y., Mann, B. H., & Masica, D. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1768 · Cited by 272
Severely Suppressed Bone Turnover and Atypical Skeletal Fragility
Visekruna, M., Wilson, D., & McKiernan, F. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2803 · Cited by 270
Crandall, C. J., Newberry, S. J., Diamant, A., Lim, Y.-W., Gellad, W. F., Booth, M. J., Motala, A., & Shekelle, P. G. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0317 · Cited by 254
Bone, H. G., Chapurlat, R., Brandi, M.-L., Brown, J. P., Czerwiński, E., Krieg, M.-A., Mellström, D., Radominski, S. C., Reginster, J.-Y., Resch, H., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1597 · Cited by 254
Black, D. M., Reid, I. R., Cauley, J. A., Cosman, F., Leung, P. C., Lakatos, P., Lippuner, K., Cummings, S. R., Hue, T. F., Mukhopadhyay, A., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2442 · Cited by 253
Imaz, I., Zegarra, P., González-Enríquez, J., Rubio, B., Alcazar, R., & Amate, J. M. (2010) · Osteoporosis International · doi:10.1007/s00198-009-1134-4 · Cited by 252
Risk of Atypical Femoral Fracture during and after Bisphosphonate Use
Schilcher, J., Koeppen, V., Aspenberg, P., & Michaëlsson, K. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1403799 · Cited by 247
Fracture risk remains reduced one year after discontinuation of risedronate
Watts, N. B., Chines, A., Olszynski, W. P., McKeever, C. D., McClung, M. R., Zhou, X., & Grauer, A. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0460-7 · Cited by 237
Boonen, S., Orwoll, E. S., Wenderoth, D., Stoner, K. J., Eusebio, R., & Delmas, P. D. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081214 · Cited by 193
Osteoporosis Medication and Reduced Mortality Risk in Elderly Women and Men
Center, J. R., Bliuc, D., Nguyen, N. D., Nguyen, T. V., & Eisman, J. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2730 · Cited by 182
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Ringe, J. D., Faber, H., Farahmand, P., & Dorst, A. (2006) · Rheumatology International · doi:10.1007/s00296-005-0004-4 · Cited by 169
Oral bisphosphonates are associated with reduced mortality after hip fracture
Beaupre, L. A., Morrish, D. W., Hanley, D. A., Maksymowych, W. P., Bell, N. R., Juby, A. G., & Majumdar, S. R. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1411-2 · Cited by 165
The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml
Carmel, A. S., Shieh, A., Bang, H., & Bockman, R. S. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1868-7 · Cited by 163
Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw
Cheung, A., & Seeman, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1002684 · Cited by 161
Potential mediators of the mortality reduction with zoledronic acid after hip fracture
Colón-Emeric, C. S., Mesenbrink, P., Lyles, K. W., Pieper, C. F., Boonen, S., Delmas, P., Eriksen, E. F., & Magaziner, J. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090704 · Cited by 159
Uhlig, K., Leff, B., Kent, D., Dy, S., Brunnhuber, K., Burgers, J. S., Greenfield, S., Guyatt, G., High, K., Leipzig, R., et al. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2659-y · Cited by 158 · cited 1×
“As has been discussed in a series of papers on guidelines,((146)) basing guidelines on randomized trials does not address the impact of coexisting conditions in many patients with a given disorder.”
Roux, C., Hofbauer, L. C., Ho, P. R., Wark, J. D., Zillikens, M. C., Fahrleitner-Pammer, A., Hawkins, F., Micaelo, M., Minisola, S., Papaioannou, N., et al. (2014) · Bone · doi:10.1016/j.bone.2013.10.006 · Cited by 158
Leu, C., Luegmayr, E., Freedman, L. P., Rodan, G. A., & Reszka, A. A. (2005) · Bone · doi:10.1016/j.bone.2005.07.023 · Cited by 154
Brown, J. P., Roux, C., Törring, O., Ho, P., Jensen, J. B., Gilchrist, N. L., Recknor, C. P., Austin, M., Wang, A., Grauer, A., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1808 · Cited by 153
Chiang, C. Y., Zebaze, R., Ghasemzadeh, A., Iuliano-Burns, S., Hardidge, A. J., & Seeman, E. (2012) · Bone · doi:10.1016/j.bone.2012.10.006 · Cited by 149
Safety issues with bisphosphonate therapy for osteoporosis
Suresh, E., Pazianas, M., & Abrahamsen, B. (2013) · Rheumatology · doi:10.1093/rheumatology/ket236 · Cited by 143
Persistence with weekly alendronate therapy among postmenopausal women
Lo, J. C.-M., Pressman, A. R., Omar, M. A., & Ettinger, B. B. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0085-2 · Cited by 140
Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy: The FLEX Study
Bauer, D. C., Schwartz, A. V., Palermo, L., Cauley, J. A., Hochberg, M. C., Santora, A., Cummings, S. R., & Black, D. M. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.1232 · Cited by 139
Self-citationDoes osteoporosis therapy invalidate FRAX for fracture prediction?
Leslie, W. D., Lix, L. M., Johansson, H., Odén, A., McCloskey, E. V., Kanis, J. А., & Program, F. T. M. B. D. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1582 · Cited by 138
Recknor, C. P., Czerwinski, E. J., Bone, H. G., Bonnick, S. L., Binkley, N., Palacios, S., Moffett, A. H., Siddhanti, S. R., Ferreira, I., Ghelani, P., et al. (2013) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e318291718c · Cited by 136
Cosman, F., Cauley, J. A., Eastell, R., Boonen, S., Palermo, L., Reid, I. R., Cummings, S. R., & Black, D. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1971 · Cited by 136
Edwards, B. J.-A., Bunta, A. D., Lane, J. M., Odvina, C. V., Rao, D. S., Raisch, D. W., McKoy, J. M., Omar, I. M., Belknap, S. M., Garg, V., et al. (2013) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.k.01181 · Cited by 128
Self-citationPathophysiology of atypical femoral fractures and osteonecrosis of the jaw
Compston, J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1804-x · Cited by 128
Self-citationSambrook, P. N., Cameron, I. D., Chen, J. S., MARCH, L. M., Simpson, J. M., Cumming, R. G., & Seibel, M. J. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1444-6 · Cited by 127
Delmas, P. D., Munoz, F., Black, D. M., Cosman, F., Boonen, S., Watts, N. B., Kendler, D. L., Eriksen, E. F., Mesenbrink, P. G., & Eastell, R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090310 · Cited by 123
Antiresorptives and Osteonecrosis of the Jaw
Yamashita, J., & McCauley, L. K. (2012) · Journal of Evidence Based Dental Practice · doi:10.1016/s1532-3382(12)70046-5 · Cited by 123
Carr, A., Thompson, P. W., & Cooper, C. C. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0166-2 · Cited by 121
Renal safety in patients treated with bisphosphonates for osteoporosis: A review
Miller, P. D., Jamal, S. A., Evenepoel, P., Eastell, R., & Boonen, S. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2058 · Cited by 117
Miyakoshi, N., Aizawa, T., Sasaki, S., Ando, S., Maekawa, S., Aonuma, H., Tsuchie, H., Sasaki, H., Kasukawa, Y., & Shimada, Y. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0617-3 · Cited by 114
Ringe, J. D., Dorst, A., Faber, H., & Ibach, K. (2004) · Rheumatology International · doi:10.1007/s00296-003-0388-y · Cited by 113
Comparison between various fracture risk assessment tools
Leslie, W. D., & Lix, L. M. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2409-3 · Cited by 113
Discontinuous calcitonin treatment of established osteoporosis—effects of withdrawal of treatment
Overgaard, K., Hansen, M. A., Nielsen, V.-A. H., Riis, B. J., & Christiansen, C. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90089-v · Cited by 108
Statins and Physical Activity in Older Men: The Osteoporotic Fractures in Men Study
Lee, D. S. H., Markwardt, S., Goeres, L. M., Lee, C. G., Eckstrom, E., Williams, C. D., Fu, R., ORWOLL, E. S., Cawthon, P. M., Stefanick, M. L., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2266 · Cited by 94
Self-citationEastell, R., Vrijens, B., Cahall, D. L., Ringe, J. D., Garnero, P., & Watts, N. B. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.342 · Cited by 93
Carvalho, N., Voss, L., Almeida, M. O., Salgado, C., & Bandeira, F. A. F. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0593 · Cited by 93
Time since prior fracture is a risk modifier for 10-year osteoporotic fractures
Giangregorio, L., & Leslie, W. D. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.35 · Cited by 92
Cauley, J. A., Wampler, N. S., Barnhart, J., Wu, L., Allison, M., Chen, Z., Hendrix, S. L., Robbins, J., & Jackson, R. D. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0634-y · Cited by 91
Timing of Subsequent Fractures after an Initial Fracture
van Geel, T. A. C. M., Huntjens, K. M., van den Bergh, J. P., Dinant, G., & Geusens, P. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0023-2 · Cited by 90
Watts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., Kleerekoper, M., Luckey, M. M., McClung, M. R., Pessah‐Pollack, R., et al. (2010) · Endocrine Practice · doi:10.4158/ep.16.6.1016 · Cited by 83
Self-citationKim, K. M., Park, W., Oh, S. Y., Kim, H. J., Nam, W., Lim, S.-K., Rhee, Y., & Cha, I. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2622-8 · Cited by 81
Hagen, J. E., Miller, A. N., Ott, S. M., Gardner, M. J., Morshed, S., Jeray, K. J., Alton, T. B., Ren, D., Abblitt, W. P., & Krieg, J. C. (2014) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.n.00075 · Cited by 81
Resolution of Osteonecrosis of the Jaw After Teriparatide [Recombinant Human PTH-(1-34)] Therapy
Lau, A. N., & Adachi, J. D. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081176 · Cited by 80
Pazianas, M., Abrahamsen, B., Eiken, P., Eastell, R., & Russell, R. G. G. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1902-4 · Cited by 79
Oh, Y., Wakabayashi, Y., Kurosa, Y., Fujita, K., & Okawa, A. (2014) · Injury · doi:10.1016/j.injury.2014.08.037 · Cited by 79
Narongroeknawin, P., Danila, M. I., Humphreys, L. G., Barasch, A., & Curtis, J. R. (2010) · Special Care in Dentistry · doi:10.1111/j.1754-4505.2009.00128.x · Cited by 78
Tennis, P. S., Rothman, K. J., Bohn, R. L., Tan, H., Zavras, A. I., Laskarides, C., Calingaert, B., & Anthony, M. S. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3292 · Cited by 77
Abrahamsen, B., Grove, E. L., & Vestergaard, P. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2469-4 · Cited by 77
Ravn, P., Christensen, J. O., Baumann, M., & Clemmesen, B. (1998) · Bone · doi:10.1016/s8756-3282(98)00044-1 · Cited by 67
Kamatari, M., Koto, S., Ozawa, N., Urao, C., Suzuki, Y., Akasaka, E., Yanagimoto, K., & Sakota, K. (2007) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-007-0768-6 · Cited by 67
Cairoli, E., Eller-Vainicher, C., Ulivieri, F. M., Zhukouskaya, V. V., Palmieri, S., Morelli, V., Beck‐Peccoz, P., & Chiodini, I. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2619-3 · Cited by 66
A Case of an Unusual Subtrochanteric Fracture in a Patient Receiving Denosumab
Paparodis, R. D., Buehring, B., Pelley, E., & Binkley, N. (2013) · Endocrine Practice · doi:10.4158/ep12367.cr · Cited by 64
Denosumab and atypical femoral fractures
Aspenberg, P. (2013) · Acta Orthopaedica · doi:10.3109/17453674.2013.859423 · Cited by 63
Brankin, E., Walker, M. D., Lynch, N., Aspray, T., Lis, Y., & Cowell, W. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112688 · Cited by 63
Hue, T. F., Cummings, S. R., Cauley, J. A., Bauer, D. C., Ensrud, K. E., Barrett-Connor, E. L., & Black, D. M. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.3634 · Cited by 63
Self-citationCooper, C. C., Fox, K. M., & BORER, J. S. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2582-4 · Cited by 62
Curtis, J. R., Yun, H., Matthews, R., Saag, K. G., & Delzell, E. (2012) · Arthritis Care & Research · doi:10.1002/acr.21638 · Cited by 61
McNabb, B., Vittinghoff, E., Schwartz, A. V., Eastell, R., Bauer, D. C., Ensrud, K. E., Rosenberg, E., Santora, A. C., Barrett-Connor, E. L., & Black, D. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1864 · Cited by 59
Self-citationMedication Persistence With Weekly Versus Daily Doses of Orally Administered Bisphosphonates
Ettinger, M. P., Gallagher, R., & MacCosbe, P. E. (2006) · Endocrine Practice · doi:10.4158/ep.12.5.522 · Cited by 56
Esophageal and gastric cancer incidence and mortality in alendronate users
Abrahamsen, B., Pazianas, M., Eiken, P., Russell, R. G. G., & Eastell, R. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1481 · Cited by 55
Schousboe, J. T., Fink, H. A., Lui, L., Taylor, B. C., & Ensrud, K. E. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060711 · Cited by 53
Brown, J. P., Roux, C., Ho, P., Bolognese, M. A., Hall, J. W., Bone, H. G., Bonnick, S. L., van den Bergh, J. P., Ferreira, I., Dakin, P., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2692-7 · Cited by 53
Atypical femoral fracture in a patient treated with denosumab
Khow, K. S. F., & Yong, T. Y. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0606-6 · Cited by 51
Chiu, W., Chien, J., Yang, W., Juang, J. J., Lee, J., & Tsai, K. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4119 · Cited by 49
Hartle, J. E., Tang, X., Kirchner, H. L., Bucaloiu, I. D., Sartorius, J. A., Pogrebnaya, Z., Akers, G., Carnero, G. E., & Perkins, R. M. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.11.037 · Cited by 42
Use of Bisphosphonates and Risk of Breast Cancer
Vestergaard, P., Fischer, L., Mele, M., Mosekilde, L., & Christiansen, P. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9463-7 · Cited by 40
Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality
van der Meulen, M. C. H., & Boskey, A. L. (2012) · Arthritis Research & Therapy · doi:10.1186/ar4013 · Cited by 40
Atypical Femur Fractures: 81 Individual Personal Histories
Schneider, J. P., Hinshaw, W. B., Su, C., & Solow, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2590 · Cited by 39
Can Change in FRAX Score Be Used to “Treat to Target”? A Population-Based Cohort Study
Leslie, W. D., Majumdar, S. R., Lix, L. M., Morin, S. N., Johansson, H., Odén, A., McCloskey, E. V., & Kanis, J. А. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2151 · Cited by 35
Akehurst, R. L., Brereton, N. J., Ariely, R., Lusa, T., Groot, M. D., Foss, P., & Boonen, S. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2010.545563 · Cited by 35
The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women
Naylor, K. E., Clowes, J. A., Finigan, J., Paggiosi, M., Peel, N. F. A., & Eastell, R. (2009) · Bone · doi:10.1016/j.bone.2009.10.043 · Cited by 34
Kang, J., Keller, J. J., & Lin, H. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1894-0 · Cited by 34
Boonen, S., Lorenc, R. S., Wenderoth, D., Stoner, K. J., Eusebio, R. A., & ORWOLL, E. S. (2012) · Bone · doi:10.1016/j.bone.2012.06.016 · Cited by 32
Peris, P., Torra, M., Olivares, V., Reyes, R., Monegal, A., Martinez-Ferrer, A., & Guañabens, N. (2011) · Bone · doi:10.1016/j.bone.2011.06.027 · Cited by 32
Ensrud, K. E., Taylor, B. C., Peters, K. W., Gourlay, M. L., Donaldson, M. G., Leslie, W. D., Blackwell, T., Fink, H. A., ORWOLL, E. S., Schousboe, J. T., et al. (2014) · BMJ · doi:10.1136/bmj.g4120 · Cited by 32
Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures
Fukuda, F., Kurinomaru, N., & Hijioka, A. (2014) · Biologics in Therapy · doi:10.1007/s13554-014-0013-5 · Cited by 31
Miller, P. D., Recker, R. R., Harris, S. T., Silverman, S. L., Felsenberg, D., Reginster, J.-Y. L., Day, B.-M., Barr, C. E., & Masanauskaite, D. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2518-z · Cited by 30
Hadji, P., Felsenberg, D., Amling, M., Hofbauer, L. C., Kandenwein, J. A., & Kurth, A. A. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2515-2 · Cited by 28
Martin, K. E., Yu, J., Campbell, H. E., Abarca, J., & White, T. (2011) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2011.17.8.596 · Cited by 28
Myocardial Infarction Risk Among Patients With Fractures Receiving Bisphosphonates
Pittman, C. B., Davis, L. A., Zeringue, A., Caplan, L., Wehmeier, K. R., Scherrer, J. F., Xian, H., Cunningham, F. E., McDonald, J. R., Arnold, A., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.08.021 · Cited by 26
Iwamoto, J., Kaori, Y. A. G. O., Satō, Y., & Matsumoto, H. (2012) · Clinical Drug Investigation · doi:10.1007/bf03261908 · Cited by 24
King, A. B., Montanya, E., Pratley, R. E., Blonde, L., Svendsen, C. B., Donsmark, M., & Sesti, G. (2012) · Endocrine Practice · doi:10.4158/ep12232.or · Cited by 21
Zanchetta, J. R., Bogado, C. E., Cisari, C., Aslanidis, S., Greisen, H., Fox, J., & Lems, W. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.524121 · Cited by 17
Weycker, D. A., Lamerato, L. E., Schooley, S., Macarios, D., Woodworth, T., Yurgin, N., & Oster, G. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2108-5 · Cited by 16
Lampropoulou-Adamidou, K. I., Tournis, S., Balanika, A. P., Antoniou, I., Stathopoulos, I., Baltas, C. S., Triantafillopoulos, I. K., & Παπαϊωάννου, Ν. (2013) · HORMONES · doi:10.14310/horm.2002.1448 · Cited by 15
Duvernoy, C. S., Yeo, A. A., Wong, M., Cox, D. A., & Kim, H. M. (2010) · Journal of Women s Health · doi:10.1089/jwh.2009.1687 · Cited by 15
Perkins, R. M., Kirchner, H. L., Matsushita, K., Bucaloiu, I. D., Norfolk, E. R., & Hartle, J. E. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07790713 · Cited by 8
Cited by
Compston, J. E., McClung, M. R., & Leslie, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32112-3 · Cited by 2,449
Self-citationEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Self-citationCamacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Self-citationCamacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Self-citation
Metadata
- Authors
- Adler, R. A., El-Hajj Fuleihan, G., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J., Favus, M. J., Greenspan, S. L., McKinney, R., Pignolo, R. J., & Sellmeyer, D. E.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-09-09
- Volume
- 31
- Issue
- 1
- Pages
- 16-35
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1777836280
- Cited by
- 672
- References
- 161
- FWCI
- 65.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.